The median PFS for patients with high expression of FAP was 6 months compared with 22 months for those with low expression of FAP, indicating that NSCLC patients with high FAP expression were more resistant to PD-1 blockade therapy (HR 2.56, 95% CI 1.69–3.87, p < 0.0001; Fig. 5a). The gene discussed is FAP; the disease is non-small cell lung carcinoma.